Beleodaq savings card: as little as $25 an infusion with commercial insurance

Beleodaq is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Beleodaq is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameBeleodaq

Authorized genericbelinostat

Regular genericbelinostat

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Beleodaq?

The original

–

Brand nameThe maker’s card

Acrotech Access Support co-pay assistance

Savings card from Acrotech Biopharma

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $25 an infusion

The card takes up to $10,000 a year off your co-pay.

In the maker’s words

“Subsequent Dates of Service: Patient will be responsible for the first $25 of the co-insurance/cost share for the Acrotech product. STAR will cover the remaining cost share for the Acrotech product at 100%.”

From the maker’s offer on acrotechpatientaccess.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Beleodaq itself, from the same company, sold without the brand name, and usually for less. For now Beleodaq is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Peripheral T-cell lymphoma (PTCL) that came back or didn’t respond

What the FDA label says

Beleodaq is a histone deacetylase inhibitor indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

Source: the FDA label for Beleodaq (Acrotech Biopharma Inc), April 7, 2025. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/beleodaq/